Krystal Biotech Receives UK Approval for Vyjuvek to Treat Skin Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Krystal Biotech announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, granted marketing authorization to Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa with mutations in the collagen type VII alpha 1 chain gene, from birth. Vyjuvek is the first genetic medicine approved in the United Kingdom for the treatment of DEB and is designed to address the root cause of the disease by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. The approval in the United Kingdom also includes flexible administration options similar to those granted in the United States, European Union, and Japan, allowing for dosing at home or in a healthcare setting, with the option for administration by patients or their caregivers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 374.680
Low
198.00
Averages
229.25
High
278.00
Current: 374.680
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell
- Strong Performance of Abivax: Abivax's stock has surged over 1,500% in the past 12 months, primarily due to the impressive efficacy of its candidate drug obefazimod for ulcerative colitis, with an expected application for approval by the end of 2026 that could significantly enhance its market share.
- Financial Growth of Krystal Biotech: Krystal Biotech's Vyjuvek generated $116.4 million in revenue in Q1, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong demand and profitability in the rare disease market.
- Market Demand for Marvell Technology: Marvell Technology reported a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and is expected to benefit from increasing demand for ASICs as AI infrastructure spending grows.
- Future Growth Potential: All three companies exhibit strong growth potential, with Abivax and Krystal Biotech driving future performance through innovative drug development, while Marvell is well-positioned to capitalize on the expansion of the AI market, potentially delivering market-beating returns.
See More
Abivax, Krystal Biotech, and Marvell's Market Potential
- Abivax's Clinical Progress: Abivax's shares have surged over 1,500% in the past 12 months, driven by strong efficacy results of its candidate obefazimod for ulcerative colitis, with an application for approval expected by the end of 2026, potentially carving out a niche in a competitive market.
- Krystal Biotech's Financial Performance: In Q1, Krystal Biotech reported revenue of $116.4 million, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong market demand and profitability in treating rare diseases, with further growth anticipated.
- Marvell's Market Demand: Marvell Technology achieved a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and as AI infrastructure spending rises, sales and earnings are expected to continue growing.
- Optimistic Industry Outlook: All three companies exhibit strong growth potential in their respective fields, with Abivax and Krystal Biotech's innovative drugs and Marvell's custom chips likely to deliver significant market returns in the coming years, attracting investor interest.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Three Stocks Outperforming the Market
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which could significantly improve health outcomes for elderly patients and meet the urgent market need for effective vaccines, potentially leading to stronger financial performance over the next two years.
- Krystal Biotech Growth Momentum: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek for a rare disease, and it is expected to continue expanding its market presence while launching more clinical trial candidates, driving sustained revenue growth.
- AMD Market Leadership: AMD's stock has surged 129% year-to-date, with its desktop CPU market share reaching 33.2% and a record revenue share of 46.2%, showcasing its strong competitive position in the rapidly growing artificial intelligence sector.
- Optimistic Investment Outlook: Despite significant stock price increases for Moderna, Krystal Biotech, and AMD, they are still viewed as worthwhile investments, with potential for higher returns in the future, particularly against the backdrop of ongoing innovation and market expansion in their respective fields.
See More
Futures Rise on Iran Deal Hopes Amid Oil Price Drop
- Futures Market Surge: Futures prices have risen on optimistic expectations surrounding a potential Iran deal, indicating increased market confidence in future economic recovery, which may attract more investors.
- Significant Oil Price Drop: Oil prices have sharply declined due to expectations of restored Iranian oil supply, which will impact the global energy market's supply-demand balance and could pressure profits for related companies.
- SpaceX IPO Trading Launch: The SpaceX IPO is set to begin trading, expected to draw significant investor interest, potentially bringing new capital inflows to the company and driving its future growth.
- Increased Market Volatility: With the sharp fluctuations in futures and oil prices, investors need to closely monitor market dynamics to adjust their investment strategies promptly and seize potential profit opportunities.
See More
Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell
- Strong Performance of Abivax: Abivax's stock has surged over 1,500% in the past 12 months, primarily due to the impressive efficacy of its candidate drug obefazimod for ulcerative colitis, with an expected application for approval by the end of 2026 that could significantly enhance its market share.
- Financial Growth of Krystal Biotech: Krystal Biotech's Vyjuvek generated $116.4 million in revenue in Q1, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong demand and profitability in the rare disease market.
- Market Demand for Marvell Technology: Marvell Technology reported a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and is expected to benefit from increasing demand for ASICs as AI infrastructure spending grows.
- Future Growth Potential: All three companies exhibit strong growth potential, with Abivax and Krystal Biotech driving future performance through innovative drug development, while Marvell is well-positioned to capitalize on the expansion of the AI market, potentially delivering market-beating returns.
See More
Abivax, Krystal Biotech, and Marvell's Market Potential
- Abivax's Clinical Progress: Abivax's shares have surged over 1,500% in the past 12 months, driven by strong efficacy results of its candidate obefazimod for ulcerative colitis, with an application for approval expected by the end of 2026, potentially carving out a niche in a competitive market.
- Krystal Biotech's Financial Performance: In Q1, Krystal Biotech reported revenue of $116.4 million, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong market demand and profitability in treating rare diseases, with further growth anticipated.
- Marvell's Market Demand: Marvell Technology achieved a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and as AI infrastructure spending rises, sales and earnings are expected to continue growing.
- Optimistic Industry Outlook: All three companies exhibit strong growth potential in their respective fields, with Abivax and Krystal Biotech's innovative drugs and Marvell's custom chips likely to deliver significant market returns in the coming years, attracting investor interest.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Three Stocks Outperforming the Market
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which could significantly improve health outcomes for elderly patients and meet the urgent market need for effective vaccines, potentially leading to stronger financial performance over the next two years.
- Krystal Biotech Growth Momentum: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek for a rare disease, and it is expected to continue expanding its market presence while launching more clinical trial candidates, driving sustained revenue growth.
- AMD Market Leadership: AMD's stock has surged 129% year-to-date, with its desktop CPU market share reaching 33.2% and a record revenue share of 46.2%, showcasing its strong competitive position in the rapidly growing artificial intelligence sector.
- Optimistic Investment Outlook: Despite significant stock price increases for Moderna, Krystal Biotech, and AMD, they are still viewed as worthwhile investments, with potential for higher returns in the future, particularly against the backdrop of ongoing innovation and market expansion in their respective fields.
See More
Futures Rise on Iran Deal Hopes Amid Oil Price Drop
- Futures Market Surge: Futures prices have risen on optimistic expectations surrounding a potential Iran deal, indicating increased market confidence in future economic recovery, which may attract more investors.
- Significant Oil Price Drop: Oil prices have sharply declined due to expectations of restored Iranian oil supply, which will impact the global energy market's supply-demand balance and could pressure profits for related companies.
- SpaceX IPO Trading Launch: The SpaceX IPO is set to begin trading, expected to draw significant investor interest, potentially bringing new capital inflows to the company and driving its future growth.
- Increased Market Volatility: With the sharp fluctuations in futures and oil prices, investors need to closely monitor market dynamics to adjust their investment strategies promptly and seize potential profit opportunities.
See More
